πŸ›οΈ Verified NIH Record β€’ Updated 2024-10-31

Directional Bilateral Thalamic Patterned Stimulation (Chronos) (NCT06325852)

🟒 Recruiting Observational / Diagnostic πŸ“‹ Clinical Research Protocol Sponsor: Alfonso Fasano

🩺 Plain-English Summary (8th-Grade Level)

Population Size and Eligible Patients: The investigators aim to recruit 5 to 10 patients with tremors who have previously undergone Ventral Intermedius Deep Brain Stimulation (VIM-DBS) treatment but have experienced early or late loss of benefits. Additionally, the investigators will enroll ten patients with essential tremor who require VIM-DBS surgery. These individuals will undergo bilateral implantation of Boston Scientific Genus Implantable Pulse Generator (IPG) devices, connected to Boston Scientific Cartesiaβ„’ 8-contact Directional Leads. Study Design: This study comprises two distinct phases. Phase 1 is a cross-sectional investigation designed to identify the optimal algorithm for patterned stimulation in the VIM region . Phase 2 is a prospective clinical trial focusing on the assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor. Objectives: The primary objective in Phase 2 is to evaluate the safety and effectiveness of bilateral VIM-DBS in individuals with essential tremor. In Phase 1, the investigators seek to explore the impact of the Chronos programming software on tremor patients who have experienced early or late loss of benefits.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (9 items).

Location: Movement Disorders Centre - Toronto Western Hospital β€” Toronto, Ontario

πŸ“‹ "Do I Qualify?" β€” 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Unwilling or inability to follow the procedures specified by the protocol.
  • Presence of significant psychiatric or cognitive condition likely to compromise the subject's ability to comply with requirements of the study protocol.
  • Untreated clinically significant depression.
  • Any current drug or alcohol abuse, as determined by the investigator.
  • History of suicidal attempt within the last 1 year prior to consent or current active suicidal ideation as determined by the investigator.
  • Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints.
  • Any terminal illness with life expectancy of \< 12 months.
  • Participation in any other interventional clinical trial (e.g. drug, device).

πŸ” Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

πŸ“ All Participating Trial Locations (1 Sites)

  • Movement Disorders Centre - Toronto Western Hospital β€” Toronto, Ontario

πŸ’° Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
πŸ›οΈ View Official NIH Record β†—